Comparative Pharmacology
Head-to-head clinical analysis: GABITRIL versus MYSOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABITRIL versus MYSOLINE.
GABITRIL vs MYSOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tiagabine inhibits gamma-aminobutyric acid (GABA) reuptake into presynaptic neurons, thereby increasing synaptic GABA levels and enhancing inhibitory neurotransmission.
Primidone is a barbiturate anticonvulsant that acts by enhancing GABA-A receptor activity and possibly by blocking sodium channels.
Initial dose: 4 mg orally twice daily. Titrate by 4-8 mg/day every 2 weeks. Maximum dose: 56 mg/day in 2-4 divided doses.
250 mg orally 3 times daily; may increase by 250 mg/day every 3 days; usual maintenance 250 mg 3-4 times daily; maximum daily dose 1500 mg.
None Documented
None Documented
Terminal elimination half-life is 7–9 hours in healthy adults. In patients with hepatic impairment, half-life is prolonged (up to 12–24 hours) due to reduced clearance. No significant effect of renal impairment.
Primidone: 5-15 hours (mean 10 hours); PEMA: 10-18 hours; Phenobarbital: 50-120 hours. Steady state achieved in 2-4 weeks due to accumulation of phenobarbital.
Approximately 70% of an oral dose is excreted in feces, 25% in urine, and 5% in bile. Renal elimination of unchanged drug is minimal (<2%); most is eliminated as metabolites.
Primidone is excreted primarily in urine; approximately 60-80% as unchanged drug and metabolites (PEMA, phenobarbital), with less than 10% in feces.
Category C
Category C
Anticonvulsant
Anticonvulsant